Attached files
| file | filename |
|---|---|
| EX-10.6.1 - EX-10.6.1 - PhaseBio Pharmaceuticals Inc | d669557dex1061.htm |
| EX-10.5 - EX-10.5 - PhaseBio Pharmaceuticals Inc | d669557dex105.htm |
| EX-10.4 - EX-10.4 - PhaseBio Pharmaceuticals Inc | d669557dex104.htm |
| EX-10.3 - EX-10.3 - PhaseBio Pharmaceuticals Inc | d669557dex103.htm |
| EX-10.2 - EX-10.2 - PhaseBio Pharmaceuticals Inc | d669557dex102.htm |
| EX-5.1 - EX-5.1 - PhaseBio Pharmaceuticals Inc | d669557dex51.htm |
| EX-3.4 - EX-3.4 - PhaseBio Pharmaceuticals Inc | d669557dex34.htm |
| EX-3.2 - EX-3.2 - PhaseBio Pharmaceuticals Inc | d669557dex32.htm |
| EX-3.1 - EX-3.1 - PhaseBio Pharmaceuticals Inc | d669557dex31.htm |
| EX-1.1 - EX-1.1 - PhaseBio Pharmaceuticals Inc | d669557dex11.htm |
| S-1/A - S-1/A - PhaseBio Pharmaceuticals Inc | d669557ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
PhaseBio Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report dated July 27, 2018, except for the recapitalization described in Note 2, as to which the date is October 5, 2018, contains an explanatory paragraph that states that PhaseBio Pharmaceuticals, Inc. has incurred recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ KPMG LLP
Philadelphia, Pennsylvania
October 5, 2018